$61.50
2.854.86%
At close: -
$61.50
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Biomarin Pharmaceutical Analyst Ratings and Price Targets | NASDAQ:BMRN | Benzinga
Biomarin Pharmaceutical Inc has a consensus price target of $97.5 based on the ratings of 30 analysts. The high is $140 issued by Truist Securities on September 25, 2023. The low is $65 issued by Baird on October 30, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, Scotiabank, and Citigroup on February 24, 2025, February 20, 2025, and February 20, 2025, respectively. With an average price target of $86.67 between Oppenheimer, Scotiabank, and Citigroup, there's an implied 40.92% upside for Biomarin Pharmaceutical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Scotiabank
Citigroup
RBC Capital
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Biomarin Pharmaceutical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/24/2025 | Buy Now | 59.35% | Oppenheimer | Leland Gershell69% | → $98 | Upgrade | Perform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | 30.08% | Scotiabank | George Farmer40% | $78 → $80 | Maintains | Sector Perform | Get Alert |
| 02/20/2025 | Buy Now | 33.33% | Citigroup | David Lebovitz64% | $81 → $82 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 13.82% | RBC Capital | Luca Issi37% | $70 → $70 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/20/2025 | Buy Now | 46.34% | Cantor Fitzgerald | Olivia Brayer57% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2025 | Buy Now | 83.74% | UBS | Eliana Merle42% | $109 → $113 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | 104.88% | Piper Sandler | Christopher Raymond54% | $122 → $126 | Maintains | Overweight | Get Alert |
| 02/20/2025 | Buy Now | 67.48% | B of A Securities | Geoff Meacham61% | $99 → $103 | Maintains | Buy | Get Alert |
| 12/12/2024 | Buy Now | 46.34% | Cantor Fitzgerald | Olivia Brayer57% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2024 | Buy Now | 54.47% | Wolfe Research | Akash Tewari43% | → $95 | Initiates | → Outperform | Get Alert |
| 10/30/2024 | Buy Now | 31.71% | Citigroup | David Lebovitz64% | $93 → $81 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | 36.59% | Canaccord Genuity | Whitney Ijem44% | $93 → $84 | Maintains | Hold | Get Alert |
| 10/30/2024 | Buy Now | 46.34% | Cantor Fitzgerald | Olivia Brayer57% | $110 → $90 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 77.24% | JP Morgan | Jessica Fye64% | $110 → $109 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 30.08% | RBC Capital | Luca Issi37% | $80 → $80 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/30/2024 | Buy Now | 70.73% | Evercore ISI Group | Cory Kasimov68% | $115 → $105 | Maintains | Outperform | Get Alert |
| 10/30/2024 | Buy Now | 72.36% | UBS | Eliana Merle42% | $104 → $106 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 5.69% | Baird | Joel Beatty64% | $72 → $65 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | — | William Blair | Tim Lugo34% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/10/2024 | Buy Now | 28.46% | Raymond James | Danielle Brill41% | → $79 | Reinstates | → Outperform | Get Alert |
| 10/04/2024 | Buy Now | 30.08% | RBC Capital | Luca Issi37% | $85 → $80 | Maintains | Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | 39.84% | Barclays | Gena Wang49% | $110 → $86 | Maintains | Overweight | Get Alert |
| 09/17/2024 | Buy Now | 26.83% | Scotiabank | George Farmer40% | $95 → $78 | Maintains | Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | 46.34% | Truist Securities | Joon Lee76% | $118 → $90 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 46.34% | Wells Fargo | Mohit Bansal69% | $115 → $90 | Maintains | Overweight | Get Alert |
| 09/17/2024 | Buy Now | 38.21% | RBC Capital | Luca Issi37% | $100 → $85 | Maintains | Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | 86.99% | B of A Securities | Geoff Meacham61% | $130 → $115 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 41.46% | Stifel | Paul Matteis41% | $115 → $87 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 46.34% | Bernstein | William Pickering37% | $116 → $90 | Maintains | Outperform | Get Alert |
| 09/13/2024 | Buy Now | 51.22% | Canaccord Genuity | Whitney Ijem44% | $93 → $93 | Maintains | Hold | Get Alert |
| 09/09/2024 | Buy Now | 78.86% | Cantor Fitzgerald | Olivia Brayer57% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 95.12% | JP Morgan | Jessica Fye64% | $111 → $120 | Maintains | Overweight | Get Alert |
| 09/05/2024 | Buy Now | 62.6% | RBC Capital | Luca Issi37% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/05/2024 | Buy Now | 54.47% | Scotiabank | George Farmer40% | $86 → $95 | Maintains | Sector Perform | Get Alert |
| 09/05/2024 | Buy Now | 91.87% | Truist Securities | Joon Lee76% | $140 → $118 | Maintains | Buy | Get Alert |
| 09/05/2024 | Buy Now | 98.37% | Piper Sandler | Christopher Raymond54% | $107 → $122 | Maintains | Overweight | Get Alert |
| 08/27/2024 | Buy Now | 73.98% | Piper Sandler | Christopher Raymond54% | $107 → $107 | Maintains | Overweight | Get Alert |
| 08/21/2024 | Buy Now | 86.99% | Stifel | Paul Matteis41% | $112 → $115 | Maintains | Buy | Get Alert |
| 08/20/2024 | Buy Now | 78.86% | Bernstein | William Pickering37% | $94 → $110 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/06/2024 | Buy Now | 95.12% | TD Cowen | Phil Nadeau66% | $125 → $120 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 39.84% | Scotiabank | George Farmer40% | $85 → $86 | Maintains | Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | 82.11% | Stifel | Paul Matteis41% | $108 → $112 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 62.6% | RBC Capital | Luca Issi37% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | 78.86% | Barclays | Gena Wang49% | $111 → $110 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 86.99% | Evercore ISI Group | Cory Kasimov68% | $113 → $115 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 78.86% | Cantor Fitzgerald | Olivia Brayer57% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2024 | Buy Now | 44.72% | Canaccord Genuity | Whitney Ijem44% | $89 → $89 | Maintains | Hold | Get Alert |
| 07/22/2024 | Buy Now | 78.86% | Cantor Fitzgerald | Olivia Brayer57% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 06/27/2024 | Buy Now | 86.99% | Wells Fargo | Mohit Bansal69% | $110 → $115 | Maintains | Overweight | Get Alert |
| 05/17/2024 | Buy Now | 17.07% | Baird | Joel Beatty64% | $104 → $72 | Downgrade | Outperform → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 83.74% | Evercore ISI Group | Cory Kasimov68% | → $113 | Initiates | → Outperform | Get Alert |
| 04/26/2024 | Buy Now | 82.11% | Morgan Stanley | Matthew Harrison62% | $115 → $112 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | 44.72% | Canaccord Genuity | Whitney Ijem44% | $91 → $89 | Maintains | Hold | Get Alert |
| 04/25/2024 | Buy Now | 78.86% | Cantor Fitzgerald | Olivia Brayer57% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 04/25/2024 | Buy Now | 47.97% | Citigroup | David Lebovitz64% | $94 → $91 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 38.21% | Scotiabank | George Farmer40% | $83 → $85 | Maintains | Sector Perform | Get Alert |
| 04/25/2024 | Buy Now | 78.86% | Wells Fargo | Mohit Bansal69% | $100 → $110 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 47.97% | Canaccord Genuity | Whitney Ijem44% | → $91 | Reiterates | Hold → Hold | Get Alert |
| 02/23/2024 | Buy Now | 62.6% | Cantor Fitzgerald | Olivia Brayer57% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 62.6% | RBC Capital | Luca Issi37% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/23/2024 | Buy Now | 73.98% | Piper Sandler | Christopher Raymond54% | $115 → $107 | Maintains | Overweight | Get Alert |
| 01/30/2024 | Buy Now | 69.11% | Baird | Joel Beatty64% | $127 → $104 | Maintains | Outperform | Get Alert |
| 12/21/2023 | Buy Now | 64.23% | Stifel | Paul Matteis41% | → $101 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 62.6% | RBC Capital | Luca Issi37% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | 62.6% | BMO Capital | Kostas Biliouris32% | $102 → $100 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | 86.99% | Piper Sandler | Christopher Raymond54% | $125 → $115 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 90.24% | Morgan Stanley | Matthew Harrison62% | $125 → $117 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 80.49% | Barclays | Gena Wang49% | $125 → $111 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 62.6% | Cantor Fitzgerald | Olivia Brayer57% | $120 → $100 | Maintains | Overweight | Get Alert |
| 10/23/2023 | Buy Now | 33.33% | Bernstein | William Pickering37% | → $82 | Upgrade | Underperform → Market Perform | Get Alert |
| 10/16/2023 | Buy Now | 95.12% | Cantor Fitzgerald | Olivia Brayer57% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/28/2023 | Buy Now | — | Raymond James | Laura Chico44% | — | Initiates | → Market Perform | Get Alert |
| 09/25/2023 | Buy Now | 127.64% | Truist Securities | Robyn Karnauskas55% | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | 95.12% | UBS | Martin Auster56% | → $120 | Initiates | → Buy | Get Alert |
| 09/15/2023 | Buy Now | 127.64% | Truist Securities | Robyn Karnauskas55% | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 95.12% | Cantor Fitzgerald | Olivia Brayer57% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 78.86% | Guggenheim | Debjit Chattopadhyay50% | → $110 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 62.6% | RBC Capital | Luca Issi37% | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/13/2023 | Buy Now | 95.12% | Cantor Fitzgerald | Olivia Brayer57% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 103.25% | Morgan Stanley | Matthew Harrison62% | $129 → $125 | Maintains | Overweight | Get Alert |
| 08/01/2023 | Buy Now | 75.61% | Stifel | Paul Matteis41% | $118 → $108 | Maintains | Buy | Get Alert |
| 08/01/2023 | Buy Now | 13.82% | Wedbush | Andreas Argyrides69% | $73 → $70 | Maintains | Neutral | Get Alert |
| 08/01/2023 | Buy Now | 95.12% | Cantor Fitzgerald | Olivia Brayer57% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 62.6% | RBC Capital | Luca Issi37% | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/27/2023 | Buy Now | 54.47% | Scotiabank | George Farmer40% | → $95 | Initiates | → Sector Perform | Get Alert |
| 07/21/2023 | Buy Now | 200.81% | B of A Securities | Geoff Meacham61% | $200 → $185 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 65.85% | BMO Capital | Kostas Biliouris32% | → $102 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/03/2023 | Buy Now | 69.11% | Canaccord Genuity | Whitney Ijem44% | $110 → $104 | Maintains | Hold | Get Alert |
| 06/30/2023 | Buy Now | 56.1% | Citigroup | David Lebowitz53% | $103 → $96 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | 106.5% | Baird | Joel Beatty64% | → $127 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | 18.7% | Wedbush | Andreas Argyrides69% | $69 → $73 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | 127.64% | Truist Securities | Robyn Karnauskas55% | $125 → $140 | Maintains | Buy | Get Alert |
| 06/14/2023 | Buy Now | 95.12% | Credit Suisse | Tiago Fauth42% | → $120 | Assumes | → Outperform | Get Alert |
| 04/27/2023 | Buy Now | 67.48% | Citigroup | David Lebowitz53% | $114 → $103 | Maintains | Neutral | Get Alert |
| 04/27/2023 | Buy Now | 95.12% | Guggenheim | Debjit Chattopadhyay50% | $125 → $120 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | 103.25% | Piper Sandler | Christopher Raymond54% | $128 → $125 | Maintains | Overweight | Get Alert |
| 04/27/2023 | Buy Now | 62.6% | RBC Capital | Luca Issi37% | → $100 | Reiterates | → Sector Perform | Get Alert |
| 04/27/2023 | Buy Now | 12.2% | Wedbush | Andreas Argyrides69% | $74 → $69 | Maintains | Neutral | Get Alert |
| 04/27/2023 | Buy Now | 95.12% | Credit Suisse | Tiago Fauth42% | $122 → $120 | Maintains | Outperform | Get Alert |
| 04/27/2023 | Buy Now | 106.5% | Baird | Joel Beatty64% | $112 → $127 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Biomarin Pharmaceutical (BMRN) stock?
The latest price target for Biomarin Pharmaceutical (NASDAQ:BMRN) was reported by Oppenheimer on February 24, 2025. The analyst firm set a price target for $98.00 expecting BMRN to rise to within 12 months (a possible 59.35% upside). 57 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biomarin Pharmaceutical (BMRN)?
The latest analyst rating for Biomarin Pharmaceutical (NASDAQ:BMRN) was provided by Oppenheimer, and Biomarin Pharmaceutical upgraded their outperform rating.
When was the last upgrade for Biomarin Pharmaceutical (BMRN)?
The last upgrade for Biomarin Pharmaceutical Inc happened on February 24, 2025 when Oppenheimer raised their price target to $98. Oppenheimer previously had a perform for Biomarin Pharmaceutical Inc.
When was the last downgrade for Biomarin Pharmaceutical (BMRN)?
The last downgrade for Biomarin Pharmaceutical Inc happened on October 30, 2024 when William Blair changed their price target from N/A to N/A for Biomarin Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Biomarin Pharmaceutical (BMRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on February 24, 2025 so you should expect the next rating to be made available sometime around February 24, 2026.
Is the Analyst Rating Biomarin Pharmaceutical (BMRN) correct?
While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a upgraded with a price target of $0.00 to $98.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $61.50, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
